Deans' stroke musings: Trial evaluating treatment of hypertension with bacteria launched

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, December 28, 2016

Trial evaluating treatment of hypertension with bacteria launched

Surprise your doctor and ask when you will be able to mist your face to control your high blood pressure. This probably will require some way for you to have a wearable continuous blood pressure monitor. So ask your doctor for that device also.
http://www.healio.com/cardiology/vascular-medicine/news/online/%7B3e2e1e6c-d4c2-43fc-bbdf-8cb12047f6bb%7D/trial-evaluating-treatment-of-hypertension-with-bacteria-launched?
AOBiome announced the launch of its phase 2 clinical trial for using live bacteria to treat hypertension.

The company is exploring the ammonia-oxidizing bacteria (B244) after the discovery of its association with BP lowering during a study on B244 on acne vulgaris, according to a press release.
“In the 2-week placebo-controlled safety study of the topical application of B244 bacterial mist on the face, we observed a dose-dependent reduction in [BP] in normotensive subjects. The effect reached statistical significance at the highest treatment dose,” Larry Weiss, MD, chief medical officer of AOBiome, said in the release. “This study provides early insight into the potential that repopulating the microbiome with ammonia-oxidizing bacteria has to treat disease and improve health."
For the study of B244 on patients with hypertension, conducted in partnership with Veristat, AOBiome will enroll 116 individuals in a 28-day, double blind, placebo-controlled trial, according to the release.
“We have long postulated that delivering nitric oxide in a host-mediated environment would regulate [BP], but, until the discovery of this bacteria, it has proven to be extremely difficult to achieve,” Joel Neutel, MD, director of research at the Orange County Research Center, Tustin, California, said in the release. “This exciting breakthrough potentially provides us with a new modality of treatment for patients with prehypertension, as well as the ability to improve [BP] control in hypertensive patients without adversely impacting patient lives.”